URL has been copied successfully!
Merck & Co. Inc. (NYSE:MRK) is nearing an all-cash deal to acquire Terns Pharmaceuticals, Inc. (NASDAQ:TERN) for roughly $6 billion, aiming to strengthen its oncology pipeline ahead of Keytruda losing U.S. patent protection, the Financial Times reported on Wednesday.
The deal could close within days, according to the report.
The companies did not immediately respond to Benzinga‘s requests for comment.
Keytruda Patent Cliff Looms
Merck is preparing for the loss of exclusivity on Keytruda, its top-selling cancer drug. The therapy generates about $30 billion annually and accounts for nearly half of the company’s revenue. U.S. patent protection could begin expiring …
Please follow us:
This post was originally published here
